Toleranzia AB

Toleranzia AB is a Swedish biotechnology firm focused on creating and bringing to market pharmaceutical solutions for rare autoimmune conditions. Its lead experimental medication, TOL2, targets myasthenia gravis, a debilitating autoimmune disorder affecting nerves and muscles. Additionally, the firm plans to advance TOL3, another investigational compound, to address ANCA vasculitis, which is an autoimmune ailment of the blood vessels. Furthermore, Toleranzia is pioneering its tolerogens technology, an innovative therapeutic approach designed to induce disease-specific immune tolerance across a range of autoimmune disorders. Established in 2011, this enterprise operates out of its headquarters located in Gothenburg, Sweden.